NanJing Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

De CEO NanJing Pharmaceutical is Liang Zhang, benoemd in Apr2022, heeft een ambtstermijn van 2.58 jaar. bezit rechtstreeks 0.012% van de aandelen van het bedrijf, ter waarde CN¥ 851.20K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 10.3 jaar en 4.6 jaar.

Belangrijke informatie

Liang Zhang

Algemeen directeur

CN¥2.1m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2.6yrs
Eigendom CEO	0.01%
Management gemiddelde ambtstermijn	10.3yrs
Gemiddelde ambtstermijn bestuur	4.6yrs

Recente managementupdates

Recent updates

NanJing Pharmaceutical's (SHSE:600713) Earnings Seem To Be Promising

Nov 06

Is NanJing Pharmaceutical (SHSE:600713) Using Too Much Debt?

Oct 28

Returns On Capital At NanJing Pharmaceutical (SHSE:600713) Paint A Concerning Picture

Sep 26

CEO

Liang Zhang (51 yo)

2.6yrs

Tenure

CN¥2,103,500

Compensatie

Mr. Liang Zhang is President and Director of NanJing Pharmaceutical Company Limited from April 28, 2022.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Liang Zhang	President & Director	2.6yrs	CN¥2.10m	0.012% CN¥ 851.2k
Jian Sun	Chief Accountant & CFO	12.6yrs	CN¥1.25m	0.012% CN¥ 851.2k
Xun Jie Luo	VP & Director	no data	CN¥1.41m	geen gegevens
Hong Xiao	Vice President	no data	CN¥1.22m	0.018% CN¥ 1.2m
Yuping Peng	Vice President	no data	CN¥1.08m	0.017% CN¥ 1.2m
Wen Jun Li	VP & Secretary of the Board of Directors	10.3yrs	CN¥1.51m	0.020% CN¥ 1.4m
Jian Zhong Tang	Vice President	no data	CN¥1.53m	0.020% CN¥ 1.4m
Chuang Feng	Vice President	no data	CN¥1.51m	0.020% CN¥ 1.4m
Qing Yang	Chief Auditor & Member of Supervisory Board	no data	CN¥501.30k	geen gegevens
Xia Yao	Employee Supervisor & VP	no data	CN¥1.34m	geen gegevens

10.3yrs

Gemiddelde duur

51.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 600713 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 10.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Liang Zhang	President & Director	2.6yrs	CN¥2.10m	0.012% CN¥ 851.2k
Xun Jie Luo	VP & Director	7.3yrs	CN¥1.41m	geen gegevens
Qing Yang	Chief Auditor & Member of Supervisory Board	12.9yrs	CN¥501.30k	geen gegevens
Xia Yao	Employee Supervisor & VP	5.7yrs	CN¥1.34m	geen gegevens
Jian Jun Zhou	Chairman	9.8yrs	CN¥2.19m	0.028% CN¥ 2.0m
Zhigang Hu	Independent Director	6.6yrs	CN¥120.00k	geen gegevens
Yindi Lu	Independent Director	2.6yrs	CN¥120.00k	geen gegevens
Jiannan Xu	Director	3.6yrs	CN¥1.79m	0.020% CN¥ 1.4m
Marco Kerschen	Director	3.2yrs	geen gegevens	geen gegevens
Chunhui Wang	Independent Director	2.6yrs	CN¥120.00k	geen gegevens

4.6yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 600713 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.6 jaar).

NanJing Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

NanJing Pharmaceutical Company Limited, Annual General Meeting, May 31, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

New major risk - Financial position

NanJing Pharmaceutical's (SHSE:600713) Earnings Seem To Be Promising

Third quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.10 in 3Q 2023)

Is NanJing Pharmaceutical (SHSE:600713) Using Too Much Debt?

NanJing Pharmaceutical Company Limited to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 19%

Returns On Capital At NanJing Pharmaceutical (SHSE:600713) Paint A Concerning Picture

Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.12 in 2Q 2023)

NanJing Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 30, 2024

NanJing Pharmaceutical Company Limited, Annual General Meeting, May 31, 2024

Full year 2023 earnings released: EPS: CN¥0.45 (vs CN¥0.47 in FY 2022)

NanJing Pharmaceutical Company Limited to Report Q1, 2024 Results on Apr 30, 2024

NanJing Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Apr 08, 2024

Third quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.16 in 2Q 2022)

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: CN¥0.47 (vs CN¥0.48 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.12 in 3Q 2021)

Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.12 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.12 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.098 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.48 (vs CN¥0.36 in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.11 in 3Q 2020)

NanJing Pharmaceutical Company Limited announced that it expects to receive CNY 999.999998 million in funding from Nanjing XinGong Investment Group Co., Ltd

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.093 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.098 (vs CN¥0.073 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.36 (vs CN¥0.33 in FY 2019)

NanJing Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 27, 2021

New 90-day low: CN¥4.06

New 90-day low: CN¥4.29

Third quarter earnings released

New 90-day low: CN¥4.52

Earnings released

New 90-day high - CN¥5.10

NanJing Pharmaceutical Company Limited to Report First Half, 2020 Results on Aug 22, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd